LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
A company we're watching closely, Propanc Health Group (PPCH), through its novel PRP treatment, is working toward clinical trials for pancreatic and ovarian cancers, followed by colorectal cancer. The company has also recently discovered indications that it's treatment could be used on several other forms of tumorous conditions.
Over the past year Propanc has made incredible strides toward achieving this goal, and just recently announced they have received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 50 years in medicine has been critical in the research and development of PRP anti-cancer treatment.
The experience Propanc's management has is nothing to gloss over. Klaus Kutz, CMO of Propanc, has prepared multiple investigational new drugs (IND) FDA applications for Sanofi, which is currently trading just under $40 a share; and Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Novartis is now trading just under $75 a share. Dr Joseph Chalil, a recent addition to the Scientific Advisory Board at Propanc, is a senior executive of Boehringer Ingleheim, one of the world's 20 leading pharmaceutical companies and a fellow of the American College of Healthcare Executives.
They are on track to adding a success story to their resume with Propanc's PRP treatment. This would be huge for investors, and judging by recent trading activity, many are loading the boat for this very reason.
With milestones on the horizon such as: a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which has been confirmed towards the end of April, followed by a commitment to submit applications for orphan drug designation in the US and EU for pancreatic and ovarian cancers; investors are anticipating some large announcements in the near future and want to be in position to benefit before the secret is out on the enormous potential of PPCH.
PPCH has been on an uptrend over the past few weeks, and that looks to continue, investors should start their research immediately.
Other companies that are listed on major exchanges, and investors should add to their watch list include:
Second Sight Medical Products, Inc. (EYES), Galena Biopharma, Inc.(GALE), Celator Pharmaceuticals (CPXX), Keryx Biopharmaceuticals Inc.(KERX)
Investors are finding tons of opportunity in biotechnology so far in 2016; we think PPCH may just be one of the most exciting of these biotech opportunities. Get yourself in position to earn profits.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $47,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.
Contact:
SOURCE: ACR Communication, LLC
